Literature DB >> 22961147

Exon-skipping drug pulls ahead in muscular dystrophy field.

Alisa Opar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22961147     DOI： 10.1038/nm0912-1314

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  2 in total

1.  Systemic administration of PRO051 in Duchenne's muscular dystrophy.

Authors:  Nathalie M Goemans; Mar Tulinius; Johanna T van den Akker; Brigitte E Burm; Peter F Ekhart; Niki Heuvelmans; Tjadine Holling; Anneke A Janson; Gerard J Platenburg; Jessica A Sipkens; J M Ad Sitsen; Annemieke Aartsma-Rus; Gert-Jan B van Ommen; Gunnar Buyse; Niklas Darin; Jan J Verschuuren; Giles V Campion; Sjef J de Kimpe; Judith C van Deutekom
Journal:  N Engl J Med       Date:  2011-03-23       Impact factor: 91.245

2.  Mutation-specific cystic fibrosis treatments on verge of approval.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2011-04       Impact factor: 53.440
  2 in total
  2 in total

Review 1.  Oligonucleotide conjugates for therapeutic applications.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2013-07

Review 2.  Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy.

Authors:  Joe W McGreevy; Chady H Hakim; Mark A McIntosh; Dongsheng Duan
Journal:  Dis Model Mech       Date:  2015-03       Impact factor: 5.758
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.